{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:14:12Z","timestamp":1783527252236,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Immuncheckpoint-Inhibitoren (ICI) werden zunehmend in der onkologischen Therapie eingesetzt. Okul\u00e4re immunvermittelte Nebenwirkungen sind selten, k\u00f6nnen jedoch die Hornhaut betreffen und bis zur kornealen Einschmelzung oder Perforation fortschreiten. Wir berichten \u00fcber zwei m\u00e4nnliche Patienten mit metastasierten Tumorerkrankungen, die unter ICI-Therapie eine schwere korneale Erkrankung entwickelten. Bei einem 65-j\u00e4hrigen Patienten mit metastasiertem Nierenzellkarzinom traten unter Pembrolizumab (\u201eprogrammed cell death protein 1 inhibitor\u201c, PD-1-Inhibitor) zun\u00e4chst rezidivierende Konjunktivitiden und epitheliale Defekte auf. Im Verlauf zeigten sich beidseits anteriore stromale Ausd\u00fcnnungen mit subepithelialer Narbenbildung. Unter intensivierter Lokaltherapie mit N-Acetylcystein und Ciclosporin A kam es zur Stabilisierung. Ein 55-j\u00e4hriger Patient mit metastasiertem nicht-kleinzelligem Lungenkarzinom entwickelte unter Atezolizumab (\u201eprogrammed death ligand 1 inhibitor\u201c, PD-L1-Inhibitor) bilaterale Hornhauterosionen mit rascher Progression zu parazentralen Ulzerationen, Hornhautperforation am rechten Auge und Descemetozele am linken Auge. Bei zus\u00e4tzlicher systemischer Tumortherapie, vorausgegangener Ganzhirnbestrahlung und Lagophthalmus war von einer multifaktoriellen Genese auszugehen. Es erfolgten eine perforierende Keratoplastik am rechten Auge und eine Amnionmembran-Transplantation am linken Auge. Bei neu auftretenden epithelialen Defekten, Ulzerationen oder stromaler Ausd\u00fcnnung unter ICI-Therapie sollte eine ICI-assoziierte korneale Einschmelzung differenzialdiagnostisch ber\u00fccksichtigt werden. Eine fr\u00fchzeitige intensive Lokaltherapie sowie eine interdisziplin\u00e4re Zusammenarbeit sind entscheidend, um eine Progression zu begrenzen.<\/jats:p>","DOI":"10.1007\/s00347-026-02458-0","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:45:35Z","timestamp":1781099135000},"page":"549-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Korneale Einschmelzung unter PD-1\/PD-L1-Inhibition","Corneal melting under PD-1\/PD-L1 inhibition"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6745-6092","authenticated-orcid":false,"given":"Leonhard Felix","family":"Jacobi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Philipp","family":"Bodenbender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2458_CR1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.940688","volume":"24","author":"MS Alkharashi","year":"2023","unstructured":"Alkharashi\u00a0MS, Al-Essa\u00a0RS, Otaif\u00a0W et\u00a0al (2023) Corneal perforation in a patient treated with atezolizumab-bevacizumab combination therapy for unresectable hepatocellular carcinoma. Am J Case Rep 24:e940688","journal-title":"Am J Case Rep"},{"key":"2458_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101489","volume":"26","author":"J Aschauer","year":"2022","unstructured":"Aschauer\u00a0J, Donner\u00a0R, Lammer\u00a0J et\u00a0al (2022) Atezolizumab-induced immune-related adverse event mimicking conjunctival metastatic disease. Am J Ophthalmol Case Rep 26:101489","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2458_CR3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1080\/09273948.2025.2456647","volume":"33","author":"D Balasubaramaniam","year":"2025","unstructured":"Balasubaramaniam\u00a0D, Yi Wen L\u00a0YW, Amir\u00a0NN et\u00a0al (2025) Corneal perforation associated with pembrolizumab: a\u00a0case report with literature review. Ocul Immunol Inflamm 33:868\u2013870","journal-title":"Ocul Immunol Inflamm"},{"key":"2458_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/eye.2012.136","volume":"26","author":"P Hossain","year":"2012","unstructured":"Hossain\u00a0P (2012) The corneal melting point. Eye (Lond) 26:1029\u20131030","journal-title":"Eye (Lond)"},{"key":"2458_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/coa.0000000000000005","volume":"2","author":"J Hsu","year":"2023","unstructured":"Hsu\u00a0J, Dixit\u00a0L, Jhanji\u00a0V et\u00a0al (2023) Corneal melt associated with cancer immunotherapy. Cornea Open 2:e0005","journal-title":"Cornea Open"},{"key":"2458_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/ICO.0000000000002490","volume":"40","author":"A Ramaekers","year":"2021","unstructured":"Ramaekers\u00a0A, Aspeslagh\u00a0S, De Brucker\u00a0N et\u00a0al (2021) Bilateral corneal perforation in a patient under anti-PD1 therapy. Cornea 40:245\u2013247","journal-title":"Cornea"},{"key":"2458_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/cxo.12973","volume":"103","author":"CC Weng","year":"2020","unstructured":"Weng\u00a0CC, Wu\u00a0CC, Lin\u00a0PY (2020) Corneal melting in a\u00a0case undergoing treatment with pembrolizumab. Clin Exp Optom 103:379\u2013381","journal-title":"Clin Exp Optom"},{"key":"2458_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1159\/000535077","volume":"14","author":"M Yamamoto","year":"2023","unstructured":"Yamamoto\u00a0M, Yamada\u00a0M, Kusumi\u00a0Y et\u00a0al (2023) Fulminant marginal keratitis induced by atezolizumab, a programmed death ligand\u20111 inhibitor for lung cancer. Case Rep Ophthalmol 14:673\u2013678","journal-title":"Case Rep Ophthalmol"},{"key":"2458_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/2008-322X.156087","volume":"10","author":"M Zamani","year":"2015","unstructured":"Zamani\u00a0M, Panahi-Bazaz\u00a0M, Assadi\u00a0M (2015) Corneal collagen cross-linking for treatment of non-healing corneal ulcers. J\u00a0Ophthalmic Vis Res 10:16\u201320","journal-title":"J Ophthalmic Vis Res"},{"key":"2458_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701951","volume":"12","author":"L Zhou","year":"2021","unstructured":"Zhou\u00a0L, Wei\u00a0X (2021) Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer. Front Immunol 12:701951","journal-title":"Front Immunol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02458-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:20:28Z","timestamp":1783524028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-026-02458-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2458"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02458-0","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.F.\u00a0Jacobi, S.\u00a0Thaler und J.-P.\u00a0Bodenbender geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}